By Elias Darido, M.D. Board-Certified Surgeon | Bariatric Surgeon Houston Weight Loss Surgery Center Published: May 26, 2026 | Last Reviewed: May 26, 2026
If you or someone you love has been living with type 2 diabetes, managing medications every day, adjusting doses, dealing with side effects, you know how exhausting it can be. That’s why I want to share something genuinely exciting that just came across my desk: a clinical trial has been authorized in the Netherlands to test the world’s first gene therapy specifically designed to treat type 2 diabetes.
This isn’t science fiction. It’s happening now. And as a surgeon who spends a great deal of time thinking about how anatomy and physiology can be changed to actually fix metabolic disease, rather than just manage it, I think this development is worth explaining to our patients in plain terms.
What Is This New Gene Therapy?
The treatment is called RJVA-001, developed by a Massachusetts-based company called Fractyl Health. Here is the core idea: instead of taking a GLP-1 medication (like Ozempic or Wegovy) every day or every week, what if your own body could produce GLP-1 naturally, only when you eat, for years, potentially from a single treatment?
That is exactly what RJVA-001 is designed to do. It is a one-time gene therapy delivered directly into the pancreas using a minimally invasive endoscopic procedure. Once delivered, it instructs the pancreatic beta cells, the same cells that produce insulin, to also produce GLP-1 in response to meals. No chronic injections. No high drug levels circulating through your system around the clock. Just your own body responding to food the way it should.
Why Does This Matter for Patients on GLP-1 Medications?
GLP-1 receptor agonists like semaglutide and tirzepatide have been transformative. We have seen real, meaningful results in our patients – better blood sugar control, significant weight loss, improvements in cardiovascular risk. But we have also seen the limitations:
- Many patients experience nausea, vomiting, and GI side effects that make it hard to stay on the medication
- The moment patients stop, the weight and blood sugar often come back
- These are lifelong medications for a lifelong disease – and that is a heavy burden
RJVA-001 takes a fundamentally different approach. Rather than flooding the bloodstream with a drug, it aims to restore the physiologic signal at its source. Triggered by meals, the pancreas secretes GLP-1, at far lower concentrations than injectable GLP-1 receptor agonist drugs. The hope is that this could provide durable metabolic control without the side effects tied to high systemic drug levels.
How Is the Therapy Delivered?
This is the part that interests me most from a procedural standpoint. RJVA-001 is not injected into the arm or taken as a pill. It is delivered via endoscopic ultrasound. A technique that uses a flexible scope passed through the mouth, combined with ultrasound imaging, to guide a needle directly into the pancreas.
Who Is Being Studied?
The Phase 1/2 first-in-human trial will enroll adults between the ages of 35 and 70 who have type 2 diabetes that is not well controlled despite being on GLP-1 receptor agonists and up to three additional oral medications. Participants must have a BMI between 27 and 40 kg/m2 and an HbA1c between 7.0 and 10.0%.
In other words, this trial is designed for patients who are already doing what they are supposed to do, taking their medications, and still not getting where they need to be. That is a population I see regularly in my practice, and the unmet need is real.
The trial will start with small groups of three patients at three escalating dose levels, followed by an optional expansion cohort of up to 20 more patients at the best dose. Patients will be monitored for 12 months and then followed for up to 5 years.
A Perspective from My Practice
As a bariatric surgeon focused on how the anatomy and physiology of the stomach and GI tract can be modified to change metabolic function, I am deeply interested in the idea that disease can be treated at its source rather than managed from the outside. This gene therapy reflects a similar philosophy: instead of compensating for a broken system with a lifelong drug, can we restore the system’s own function? This idea of “physiologic restoration” resonates with what we do at Houston Weight Loss Surgery Center.
We are not yet at the point where this therapy is available to patients – the first human dose has not yet been given. But trials like this represent a turning point in how we think about type 2 diabetes. For the first time, we are asking seriously: could this be a disease we treat once, rather than manage every day?
What Should Our Patients Do Right Now?
If you are a patient with type 2 diabetes who is struggling to control your blood sugar despite medications, give us a call because we can help you. Bariatric surgery like gastric bypass and gastric sleeve surgery has strong evidence for producing durable remission or significant improvement in type 2 diabetes.
Key Clinical Points
- RJVA-001 is the first AAV-based gene therapy candidate to enter clinical development for type 2 diabetes, receiving authorization in the Netherlands in May 2026.
- The therapy is designed to enable the pancreas to produce GLP-1 naturally in response to meals; a physiologic approach compared to chronic high-dose injectable medications.
- It is delivered via endoscopic ultrasound, a minimally invasive, scope-based procedure, directly into the pancreas.
- The Phase 1/2 trial targets patients with inadequately controlled T2D who are already on GLP-1 receptor agonists; first patient dosing and preliminary data are expected in the second half of 2026.
- While gene therapy for diabetes is not yet available to patients, proven surgical options, like gastric sleeve surgery, for metabolic disease are available today and may significantly improve or resolve type 2 diabetes.
If you have questions about your options for managing obesity or type 2 diabetes – including procedures that may reduce or eliminate your need for medication – I encourage you to schedule a consultation with our team. We are here to help you understand every tool available, from today’s proven surgical approaches to the therapies that are coming.
Elias Darido, M.D. Houston Weight Loss Surgery Center
Schedule an Appointment (832) 963-1803
Published: May 26, 2026. Last Reviewed: May 26, 2026
The information in this post is intended for general educational purposes and does not constitute medical advice. Please consult with a qualified physician regarding your individual health situation.